Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis

• US 10,144,761 B2
• Filed: 06/20/2016
• Issued: 12/04/2018
• Est. Priority Date: 06/19/2015
• Status: Active Grant

• Current Assignee: Artivila Innovation Center Limited
• Original Assignee: Hanlin Scientific, Inc.
• Inventors: Han, Guoxia
• Primary Examiner(s): Reynolds, Fred H
• Application Number:
  US15/186,988
• Publication Number:
  US 20160368945A1
• Time in Patent Office: 897 Days
• Field of Search: None
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07F 5/022 without C-boron linkages
• CPC Class Codes: C07F 5/025 Boronic and borinic acid compounds
• CPC Class Codes: C07K 5/06139 with the first amino acid being heterocyclic
• CPC Class Codes: C07K 5/06191 containing heteroatoms different from O, S, or N

Abstract

Useful chiral specific boron-containing compounds, such as boronate, boronate esters, boranamines, borane diamines, boranamine thioesters, and boronic mono/di-thioesters, have been prepared. These compounds and compositions containing them are useful as anti-cancer or anti-amyloidosis agents.

Claims

1. An optically active compound represented by the following formula:

2. A pharmaceutical composition comprising a pharmaceutically effective a mount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable carriers, diluents, or excipients.

5. A method of treating multiple myeloma in a human or mammal host in need of such treatment, comprising administering to said host an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

3. An optically active compound represented by the following formula:

4. A pharmaceutical composition comprising a pharmaceutically effective a mount of a compound of claim 3 or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable carriers, diluents, or excipients.

6. A method of treating multiple myeloma in a human or mammal host in need of such treatment, comprising administering to said host an effective amount of a compound of claim 3 or a pharmaceutically acceptable salt thereof.